Next generation Cryoimmunostaining™ Suite revealed Singapore, June 2020 – 18 months after premiering at the 2019 Medlab Asia exhibition in Singapore, X-ZELL’s game-changing Cryoimmunostaining™ Suite is about to receive a facelift. According to X-ZELL’s Head of...
X-ZELL part of Galen Growth’s 2020 HealthTech Cohort Singapore, May 2020 – X-ZELL is one of 23 start-ups selected to be part of Galen Growth’s inaugural HealthTech Cohort, an acceleration and networking initiative designed to champion healthcare innovation from across...
Essex Bio-Technology Joins X-ZELL Seed+ Investment Round Singapore/Hong Kong, April 2020 – Rare cell detection specialist X-ZELL has entered into an investment agreement with Essex Bio-Investment, a wholly owned subsidiary of Essex Bio-Technology Ltd (“EssexBio”)....
X-ZELL featured in German life science magazine Laborjournal Freiburg, April 2020 – X-ZELL has been featured in the April edition of Laborjournal, one of Germany’s leading life science publications. The extensive company profile, penned by science journalist Dr...
INTERVIEW Krebs im BLUT Due to the overwhelming response to X-ZELL’s recent Live Sessions tour around Germany, we sat down with X-ZELL Founder & CEO, Dr Sebastian Bhakdi, to interview him in his native language. Singapur, Februar 2020 – Der deutsche Arzt Dr....
X-ZELL Cryoimmunostaining™ technology live in Europe Brussels, February 2020 – Following the official European launch of X-ZELL’s Cryoimmunostaining™ Suite in November 2019, the Singapore start-up will be holding a series of Live Sessions in 2020 in order to introduce...
